Related Experiment Video
Updated: Jun 26, 2025
05:25
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
19.2K
Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia using Patient-Reported Outcomes: Protocol
Alexander P Glaser1, Abigail R Smith2, Dacey Maglaque1
1NorthShore University HealthSystem.
Research Square
|May 20, 2024
Summary
This study integrates enhanced patient-reported outcomes (PROs) to improve assessment and management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Findings aim to refine personalized care and clinical guidelines for better patient outcomes.
Area of Science:
- Urology
- Patient-Reported Outcomes Research
- Health Services Research
Background:
- Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) significantly impact quality of life in older men.
- Current assessment tools like the American Urological Association Symptom Index (AUA-SI) have limitations, omitting key symptoms such as pain and incontinence.
- There is a need for comprehensive patient-reported outcome (PRO) tools to better capture the full spectrum of LUTS and improve patient care.
Approach:
- Prospective observational study recruiting men aged ≥ 50 years with LUTS secondary to BPH.
- Utilizing the LURN Symptom Index (SI)-29 alongside AUA-SI and other non-urologic PROs for broad symptom evaluation.
- Collecting data via electronic health records and PROs, analyzing predictive power for symptom trajectories and treatment responses.
Key Points:
- Integrating enhanced PROs into routine clinical practice to refine symptom assessment and treatment monitoring.
- Examining psychometric properties of LURN SIs, including reliability and clinically meaningful differences.
- Developing care-coordination recommendations for managing persistent symptoms and comorbidities.
Conclusions:
- This study is expected to improve personalized care strategies for LUTS/BPH management.
- Findings may lead to updates in clinical guidelines and enhanced health management for affected men.
- Revolutionizing LUTS/BPH management through nuanced insights into patient experiences and outcomes.
Related Concept Videos
01:20Disorders of the Male Reproductive System
395
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
395
01:26Methods of Documentation II: POMR
939
The Problem-Oriented Medical Record (POMR) revolutionized medical record-keeping by introducing a systematic approach focusing on the patient's problems rather than merely listing symptoms. Dr. Lawrence Weed's introduction of this method in the 1960s marked a significant advancement in medical documentation. The POMR framework consists of four key components: the database, problem list, plan of care, and progress notes.
939
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
01:11Guidelines for Writing Outcome
2.8K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
2.8K